187 related articles for article (PubMed ID: 36145648)
1. Fragment-Based and Structural Investigation for Discovery of JNK3 Inhibitors.
Duong MTH; Ahn HC
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145648
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis.
Xie X; Gu Y; Fox T; Coll JT; Fleming MA; Markland W; Caron PR; Wilson KP; Su MS
Structure; 1998 Aug; 6(8):983-91. PubMed ID: 9739089
[TBL] [Abstract][Full Text] [Related]
3. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.
Fricker M; Lograsso P; Ellis S; Wilkie N; Hunt P; Pollack SJ
Arch Biochem Biophys; 2005 Jun; 438(2):195-205. PubMed ID: 15907786
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.
Kamenecka T; Habel J; Duckett D; Chen W; Ling YY; Frackowiak B; Jiang R; Shin Y; Song X; LoGrasso P
J Biol Chem; 2009 May; 284(19):12853-61. PubMed ID: 19261605
[TBL] [Abstract][Full Text] [Related]
5. Identification and neuroprotective evaluation of a potential c-Jun N-terminal kinase 3 inhibitor through structure-based virtual screening and in-vitro assay.
Rajan RK; Ramanathan M
J Comput Aided Mol Des; 2020 Jun; 34(6):671-682. PubMed ID: 32040807
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease.
Shuai W; Bu F; Zhu Y; Wu Y; Xiao H; Pan X; Zhang J; Sun Q; Wang G; Ouyang L
J Med Chem; 2023 Jan; 66(2):1273-1300. PubMed ID: 36649216
[TBL] [Abstract][Full Text] [Related]
7. JSAP1, a novel jun N-terminal protein kinase (JNK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway.
Ito M; Yoshioka K; Akechi M; Yamashita S; Takamatsu N; Sugiyama K; Hibi M; Nakabeppu Y; Shiba T; Yamamoto KI
Mol Cell Biol; 1999 Nov; 19(11):7539-48. PubMed ID: 10523642
[TBL] [Abstract][Full Text] [Related]
8. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.
Scapin G; Patel SB; Lisnock J; Becker JW; LoGrasso PV
Chem Biol; 2003 Aug; 10(8):705-12. PubMed ID: 12954329
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential JNK3 inhibitors through virtual screening, molecular docking and molecular dynamics simulation as therapeutics for Alzheimer's disease.
Devi B; Jangid K; Kumar N; Kumar V; Kumar V
Mol Divers; 2024 Apr; ():. PubMed ID: 38573427
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.
Zhu Y; Shuai W; Zhao M; Pan X; Pei J; Wu Y; Bu F; Wang A; Ouyang L; Wang G
J Med Chem; 2022 Mar; 65(5):3758-3775. PubMed ID: 35200035
[TBL] [Abstract][Full Text] [Related]
11. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
12. The structure-based optimization of 3-substituted indolin-2-one derivatives as potent and isoform-selective c-Jun N-terminal kinase 3 (JNK3) inhibitors and biological evaluation.
Li Z; Zhu G; Liu X; Gao T; Fang F; Dou X; Li Y; Zheng R; Jin H; Zhang L; Liu Z; Zhang L
Eur J Med Chem; 2023 Mar; 250():115167. PubMed ID: 36764123
[TBL] [Abstract][Full Text] [Related]
13. A single c-Jun N-terminal kinase isoform (JNK3-p54) is an effector in both neuronal differentiation and cell death.
Waetzig V; Herdegen T
J Biol Chem; 2003 Jan; 278(1):567-72. PubMed ID: 12401814
[TBL] [Abstract][Full Text] [Related]
14. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
Dou X; Huang H; Li Y; Jiang L; Wang Y; Jin H; Jiao N; Zhang L; Zhang L; Liu Z
J Med Chem; 2019 Jul; 62(14):6645-6664. PubMed ID: 31268308
[TBL] [Abstract][Full Text] [Related]
15. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.
Bogoyevitch MA; Boehm I; Oakley A; Ketterman AJ; Barr RK
Biochim Biophys Acta; 2004 Mar; 1697(1-2):89-101. PubMed ID: 15023353
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Potent and Selective JNK3 Inhibitor with Neuroprotective Effect Against Amyloid β-Induced Neurotoxicity in Primary Rat Neurons.
Jun J; Baek J; Yang S; Moon H; Kim H; Cho H; Hah JM
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681742
[TBL] [Abstract][Full Text] [Related]
17. Deletion of the c-Jun N-terminal kinase 3 gene protects neonatal mice against cerebral hypoxic-ischaemic injury.
Pirianov G; Brywe KG; Mallard C; Edwards AD; Flavell RA; Hagberg H; Mehmet H
J Cereb Blood Flow Metab; 2007 May; 27(5):1022-32. PubMed ID: 17063149
[TBL] [Abstract][Full Text] [Related]
18. The JNK1/JNK3 interactome--contributions by the JNK3 unique N-terminus and JNK common docking site residues.
Chen WK; Yeap YY; Bogoyevitch MA
Biochem Biophys Res Commun; 2014 Oct; 453(3):576-81. PubMed ID: 25301550
[TBL] [Abstract][Full Text] [Related]
19. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.
Bogoyevitch MA
Bioessays; 2006 Sep; 28(9):923-34. PubMed ID: 16937364
[TBL] [Abstract][Full Text] [Related]
20. Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design.
Moore J; Abdul-Manan N; Fejzo J; Jacobs M; Lepre C; Peng J; Xie X
J Synchrotron Radiat; 2004 Jan; 11(Pt 1):97-100. PubMed ID: 14646145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
